|
|
 |
|
Viewing report
|
|
|
|
The Pharmaceutical Market: Netherlands
Espicom Business Intelligence Ltd, Sep 2009, Pages: 94
This in-depth pharmaceutical market report is ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, pricing/reimbursement, intellectual property, health facilities and government policy. The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data for raw materials and finished products and essential industry contacts. Included with the report are 3 free quarterly updated outlook reports, enabling you to keep up to date with market developments for a year.
Executive Summary
The Kingdom of the Netherlands is situated in Western Europe and occupies a total land area of 33,939 square kilometers. Germany lies to the east, Belgium to the south and the North Sea to the north and west.
The country has a long history of providing accessible healthcare, although resources are comparatively low for a West European country.
The government has introduced a mandatory health insurance scheme, which commenced in January 2006. This replaced the previous two-tier system and provides basic health insurance cover for acute care services with a separate scheme for long term medical care.
The new health insurance act has substantially increased price competition amongst insurers and healthcare providers resulting in one of the most market-oriented healthcare systems in Europe.
Per capita expenditure on pharmaceutical products is considerably lower than nearby Belgium, France or Germany at US$573 in 2009.
Comparatively low spending on pharmaceuticals has been achieved through heavy reliance on generic products which now account for more than half the market by volume. Generic revenues contracted in 2008 as a result of a price war between suppliers in response to health insurers implementing a preferential supplier policy.
The Netherlands has a well respected contract research and development environment, although few multinationals currently have manufacturing plants there.
Customers who bought this item also bought
The Pharmaceutical Market: Portugal
The Pharmaceutical Market: Switzerland
The Pharmaceutical Market: Sweden
The Pharmaceutical Market: Mexico
The Pharmaceutical Market: Romania
The Pharmaceutical Market: Colombia
The Pharmaceutical Market: Malaysia
The Pharmaceutical Market: Morocco
The Pharmaceutical Market: Ukraine
The Pharmaceutical Market: Bulgaria
The Pharmaceutical Market: Ireland
The Pharmaceutical Market: Belgium
|
|
|
|
